KKR & Co. L.P. and Bushu Pharmaceuticals Ltd. announced on December 20 a definitive agreement under which KKR will acquire all shares in Bushu Pharmaceuticals from Asian private equity firm BPEA EQT.
KKR is making its investment from one of its Asia-focused investment funds. The transaction is expected to be completed in Q1 2023, subject to customary approvals and closing conditions. Following the transaction’s completion, KKR aims to accelerate Bushu’s growth and further position it as a leading contract development and manufacturing organization (CDMO) for the pharmaceuticals market in Japan and worldwide. Terms of the deal were not disclosed.
Bushu Pharmaceuticals Ltd. was established in August 1998 as an independent pharmaceutical contract manufacturer. Bushu carries out pharmaceutical drug product contract manufacturing and packaging of clinical trials and commercial products in accordance with the latest GMP standards.
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, credit and real assets, with strategic partners that manage hedge funds. The firm has a long track record of supporting health care companies globally, having invested approximately $17 billion in the sector since 2004.
According to data captured from the LevinPro HC database, this represents the 38th CDMO transaction of 2022. This is a slight increase from January 1, 2021, through December 20, 2021, when 35 CDMO transactions were announced.
